» Articles » PMID: 38383479

A Tumor Suppressor Protein Encoded by CircKEAP1 Inhibits Osteosarcoma Cell Stemness and Metastasis by Promoting Vimentin Proteasome Degradation and Activating Anti-tumor Immunity

Overview
Publisher Biomed Central
Specialty Oncology
Date 2024 Feb 21
PMID 38383479
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteosarcoma (OS) is one of most commonly diagnosed bone cancer. Circular RNAs (circRNAs) are a class of highly stable non-coding RNA, the majority of which have not been characterized functionally. The underlying function and molecular mechanisms of circRNAs in OS have not been fully demonstrated.

Method: Microarray analysis was performed to identify circRNAs that are differentially-expressed between OS and corresponding normal tissues. The biological function of circKEAP1 was confirmed in vitro and in vivo. Mass spectrometry and western blot assays were used to identify the circKEAP1-encoded protein KEAP1-259aa. The molecular mechanism of circKEAP1 was investigated by RNA sequencing and RNA immunoprecipitation analyses.

Results: Here, we identified a tumor suppressor circKEAP1, originating from the back-splicing of exon2 of the KEAP1 gene. Clinically, circKEAP1 is downregulated in OS tumors and associated with better survival in cancer patients. N6-methyladenosine (m6A) at a specific adenosine leads to low expression of circKEAP1. Further analysis revealed that circKEAP1 contained a 777 nt long ORF and encoded a truncated protein KEAP1-259aa that reduces cell proliferation, invasion and tumorsphere formation of OS cells. Mechanistically, KEAP1-259aa bound to vimentin in the cytoplasm to promote vimentin proteasome degradation by interacting with the E3 ligase ARIH1. Moreover, circKEAP1 interacted with RIG-I to activate anti-tumor immunity via the IFN-γ pathway.

Conclusion: Taken together, our findings characterize a tumor suppressor circKEAP1 as a key tumor suppressor regulating of OS cell stemness, proliferation and migration, providing potential therapeutic targets for treatment of OS.

Citing Articles

The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.

Shi T, Zhang H, Chen Y Cell Biosci. 2025; 15(1):27.

PMID: 39987091 PMC: 11846233. DOI: 10.1186/s13578-025-01368-z.


Noncoding RNA-encoded peptides in cancer: biological functions, posttranslational modifications and therapeutic potential.

Tan S, Yang W, Ren Z, Peng Q, Xu X, Jiang X J Hematol Oncol. 2025; 18(1):20.

PMID: 39972384 PMC: 11841355. DOI: 10.1186/s13045-025-01671-9.


A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination.

Guan C, Gao J, Zou X, Shi W, Hao Y, Ge Y Adv Sci (Weinh). 2025; 12(10):e2409173.

PMID: 39836545 PMC: 11904980. DOI: 10.1002/advs.202409173.


Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies.

Shen J, Lai Y, Wu Y, Lin X, Zhang C, Liu H Cancer Biol Med. 2024; 21(10).

PMID: 39475222 PMC: 11523277. DOI: 10.20892/j.issn.2095-3941.2024.0231.


Roles of small peptides encoded by non-coding RNAs in tumor invasion and migration.

Liu J, Chang X, Manji L, Xu Z, Xiao W Front Pharmacol. 2024; 15:1442196.

PMID: 39351098 PMC: 11439703. DOI: 10.3389/fphar.2024.1442196.


References
1.
Shao W, Li J, Piao Q, Yao X, Li M, Wang S . FRMD3 inhibits the growth and metastasis of breast cancer through the ubiquitination-mediated degradation of vimentin and subsequent impairment of focal adhesion. Cell Death Dis. 2023; 14(1):13. PMC: 9834407. DOI: 10.1038/s41419-023-05552-2. View

2.
Wang X, Ma R, Zhang X, Cui L, Ding Y, Shi W . Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions. Mol Cancer. 2021; 20(1):121. PMC: 8461955. DOI: 10.1186/s12943-021-01415-6. View

3.
Zimmerman S, Peters N, Altaras A, Berg C . Optimized RNA ISH, RNA FISH and protein-RNA double labeling (IF/FISH) in Drosophila ovaries. Nat Protoc. 2013; 8(11):2158-79. PMC: 4126239. DOI: 10.1038/nprot.2013.136. View

4.
Tian H, Lian R, Li Y, Liu C, Liang S, Li W . AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation. Nat Commun. 2020; 11(1):5127. PMC: 7550350. DOI: 10.1038/s41467-020-18929-0. View

5.
Liu C, Lin H, Tang M, Wang Y . Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 2015; 6(18):15966-83. PMC: 4599250. DOI: 10.18632/oncotarget.3862. View